Diagnostic Performance of Dynamic Contrast-Enhanced 3T MR Imaging for Characterization of Orbital Lesions: Validation in a Large Prospective Study

References

1. 1.↵
   1. Shields JA,
   2. Shields CL,
   3. Scartozzi R

   . Survey of 1264 patients with orbital tumors and simulating lesions. Ophthalmology 2004;111:997–1008 doi:10.1016/j.ophtha.2003.01.002 pmid:15121380

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Demirci H,
   2. Shields CL,
   3. Shields JA, et al

   . Orbital tumors in the older adult population. Ophthalmology 2002;109:243–48 doi:10.1016/s0161-6420(01)00932-0 pmid:11825802

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Kansakar P,
   2. Sundar G

   . Vision loss associated with orbital surgery: a major review. Orbit 2020;39:197–208 doi:10.1080/01676830.2019.1658790 pmid:31573370

   CrossRefPubMed
4. 4.↵
   1. Purgason PA,
   2. Hornblass A

   . Complications of surgery for orbital tumors. Ophthalmic Plast Reconstr Surg 1992;8:88–93 doi:10.1097/00002341-199206000-00002 pmid:1520662

   CrossRefPubMed
5. 5.↵
   1. Lecler A,
   2. Boucenna M,
   3. Lafitte F, et al

   . Usefulness of colour Doppler flow imaging in the management of lacrimal gland lesions. Eur Radiol 2017;27:779–89 doi:10.1007/s00330-016-4438-8 pmid:27271920

   CrossRefPubMed
6. 6.↵
   1. Jaju A,
   2. Rychlik K,
   3. Ryan ME

   . MRI of pediatric orbital masses: role of quantitative diffusion-weighted imaging in differentiating benign from malignant lesions. Clin Neuroradiol 2020;30:615–24 doi:10.1007/s00062-019-00790-4 pmid:31134316

   CrossRefPubMed
7. 7.↵
   1. Eissa L,
   2. Abdel Razek AA,
   3. Helmy E

   . Arterial spin labeling and diffusion-weighted MR imaging: utility in differentiating idiopathic orbital inflammatory pseudotumor from orbital lymphoma. Clin Imaging 2021;71:63–68 doi:10.1016/j.clinimag.2020.10.057 pmid:33171369

   CrossRefPubMed
8. 8.↵
   1. ElKhamary SM,
   2. Galindo-Ferreiro A,
   3. AlGhafri L, et al

   . Characterization of diffuse orbital mass using apparent diffusion coefficient in 3-Tesla MRI. Eur J Radiol Open 2018;5:52–57 doi:10.1016/j.ejro.2018.03.001 pmid:29719859

   CrossRefPubMed
9. 9.↵
   1. Phuttharak W,
   2. Boonrod A,
   3. Patjanasoontorn N, et al

   . The roles of the diffusion-weighted imaging in orbital masses. J Med Imaging Radiat Oncol 2017;61:753–58 doi:10.1111/1754-9485.12627 pmid:28664638

   CrossRefPubMed
10. 10.↵
    1. Lecler A,
    2. Duron L,
    3. Zmuda M, et al

    . Intravoxel incoherent motion (IVIM) 3T MRI for orbital lesion characterization. Eur Radiol 2021;31:14–23 doi:10.1007/s00330-020-07103-1 pmid:32740820

    CrossRefPubMed
11. 11.↵
    1. Soussan JB,
    2. Deschamps R,
    3. Sadik JC, et al

    . Infraorbital nerve involvement on magnetic resonance imaging in European patients with IgG4-related ophthalmic disease: a specific sign. Eur Radiol 2017;27:1335–43 doi:10.1007/s00330-016-4481-5 pmid:27436015

    CrossRefPubMed
12. 12.↵
    1. Sepahdari AR,
    2. Aakalu VK,
    3. Setabutr P, et al

    . Indeterminate orbital masses: restricted diffusion at MR imaging with echo-planar diffusion-weighted imaging predicts malignancy. Radiology 2010;256:554–64 doi:10.1148/radiol.10091956 pmid:20656840

    CrossRefPubMed
13. 13.↵
    1. Shor N,
    2. Sené T,
    3. Zuber K, et al

    . Discriminating between IgG4-related orbital disease and other causes of orbital inflammation with intra voxel incoherent motion (IVIM) MR imaging at 3T. Diagn Interv Imaging 2021;102:727–34 doi:10.1016/j.diii.2021.06.006 pmid:34326025

    CrossRefPubMed
14. 14.↵
    1. Cuenod CA,
    2. Balvay D

    . Perfusion and vascular permeability: basic concepts and measurement in DCE-CT and DCE-MRI. Diagn Interv Imaging 2013;94:1187–204 doi:10.1016/j.diii.2013.10.010 pmid:24211260

    CrossRefPubMed
15. 15.↵
    1. Jost SC,
    2. Ackerman JW,
    3. Garbow JR, et al

    . Diffusion-weighted and dynamic contrast-enhanced imaging as markers of clinical behavior in children with optic pathway glioma. Pediatr Radiol 2008;38:1293–99 doi:10.1007/s00247-008-1003-x pmid:18846370

    CrossRefPubMed
16. 16.↵
    1. Xu XQ,
    2. Hu H,
    3. Liu H, et al

    . Benign and malignant orbital lymphoproliferative disorders: differentiating using multiparametric MRI at 3.0T. J Magn Reson Imaging 2016;45:167–76 doi:10.1002/jmri.25349 pmid:27299917

    CrossRefPubMed
17. 17.↵
    1. Li X,
    2. Wu X,
    3. Qian J, et al

    . Differentiation of lacrimal gland tumors using the multi-model MRI: classification and regression tree (CART)-based analysis. Acta Radiol 2022;63:923–32 doi:10.1177/02841851211021039 pmid:34058846

    CrossRefPubMed
18. 18.↵
    1. Yuan Y,
    2. Kuai XP,
    3. Chen XS, et al

    . Assessment of dynamic contrast-enhanced magnetic resonance imaging in the differentiation of malignant from benign orbital masses. Eur J Radiol 2013;82:1506–11 doi:10.1016/j.ejrad.2013.03.001 pmid:23561057

    CrossRefPubMed
19. 19.↵
    1. Jittapiromsak N,
    2. Hou P,
    3. Liu HL, et al

    . Dynamic contrast-enhanced MRI of orbital and anterior visual pathway lesions. Magn Reson Imaging 2018;51:44–50 doi:10.1016/j.mri.2018.04.016 pmid:29709464

    CrossRefPubMed
20. 20.↵
    1. Haradome K,
    2. Haradome H,
    3. Usui Y, et al

    . Orbital lymphoproliferative disorders (OLPDs): value of MR imaging for differentiating orbital lymphoma from benign OPLDs. AJNR Am J Neuroradiol 2014;35:1976–82 doi:10.3174/ajnr.A3986 pmid:24874530

    Abstract/FREE Full Text
21. 21.↵
    1. Hu H,
    2. Xu XQ,
    3. Liu H, et al

    . Orbital benign and malignant lymphoproliferative disorders: differentiation using semi-quantitative and quantitative analysis of dynamic contrast-enhanced magnetic resonance imaging. Eur J Radiol 2017;88:88–94 doi:10.1016/j.ejrad.2016.12.035 pmid:28189215

    CrossRefPubMed
22. 22.↵
    1. Xian J,
    2. Zhang Z,
    3. Wang Z, et al

    . Evaluation of MR imaging findings differentiating cavernous haemangiomas from schwannomas in the orbit. Eur Radiol 2010;20:2221–28 doi:10.1007/s00330-010-1774-y pmid:20393718

    CrossRefPubMed
23. 23.↵
    1. Ro SR,
    2. Asbach P,
    3. Siebert E, et al

    . Characterization of orbital masses by multiparametric MRI. Eur J Radiol 2016;85:324–36 doi:10.1016/j.ejrad.2015.11.041 pmid:26781137

    CrossRefPubMed
24. 24.↵
    1. Lecler A,
    2. Balvay D,
    3. Cuenod CA, et al

    . Quality-based pharmacokinetic model selection on DCE-MRI for characterizing orbital lesions. J Magn Reson Imaging 2019;50:1514–25 doi:10.1002/jmri.26747 pmid:30989761

    CrossRefPubMed
25. 25.↵
    1. Wang Y,
    2. Song L,
    3. Guo J, et al

    . Value of quantitative multiparametric MRI in differentiating pleomorphic adenomas from malignant epithelial tumors in lacrimal gland. Neuroradiology 2020;62:1141–47 doi:10.1007/s00234-020-02455-3 pmid:32430642

    CrossRefPubMed
26. 26.↵
    1. Hou Y,
    2. Xie X,
    3. Chen J, et al

    . Bag-of-features-based radiomics for differentiation of ocular adnexal lymphoma and idiopathic orbital inflammation from contrast-enhanced MRI. Eur Radiol 2021;31:24–33 doi:10.1007/s00330-020-07110-2 pmid:32789530

    CrossRefPubMed
27. 27.↵
    1. Qian W,
    2. Xu XQ,
    3. Hu H, et al

    . Dynamic contrast-enhanced MRI in orbital lymphoproliferative disorders: effects of region of interest selection methods on time efficiency, measurement reproducibility, and diagnostic ability. J Magn Reson Imaging 2018;47:1298–305 doi:10.1002/jmri.25859 pmid:28922524

    CrossRefPubMed
28. 28.↵
    1. Gaddikeri S,
    2. Gaddikeri RS,
    3. Tailor T, et al

    . Dynamic contrast-enhanced MR imaging in head and neck cancer: techniques and clinical applications. AJNR Am J Neuroradiol 2016;37:588–95 doi:10.3174/ajnr.A4458 pmid:26427839

    Abstract/FREE Full Text
29. 29.↵
    1. Benchoufi M,
    2. Matzner-Lober E,
    3. Molinari N, et al

    . Interobserver agreement issues in radiology. Diagn Interv Imaging 2020;101:639–41 doi:10.1016/j.diii.2020.09.001 pmid:32958434

    CrossRefPubMed
30. 30.↵
    1. Russo C,
    2. Strianese D,
    3. Perrotta M, et al

    . Multi-parametric magnetic resonance imaging characterization of orbital lesions: a triple blind study. Semin Ophthalmol 2020;35:95–102 doi:10.1080/08820538.2020.1742358 pmid:32298217

    CrossRefPubMed
31. 31.↵
    1. Tanaka A,
    2. Mihara F,
    3. Yoshiura T, et al

    . Differentiation of cavernous hemangioma from schwannoma of the orbit: a dynamic MRI study. AJR Am J Roentgenol 2004;183:1799–804 doi:10.2214/ajr.183.6.01831799 pmid:15547232

    CrossRefPubMed
32. 32.↵
    International Society for the Study of Vascular Anomalies. Classification. https://www.issva.org/classification. Accessed August 26, 2023
33. 33.↵
    1. Tawfik HA,
    2. Dutton JJ

    . Orbital vascular anomalies: a nomenclatorial, etiological, and nosologic conundrum. Ophthalmic Plast Reconstr Surg 2022;38:108–21 doi:10.1097/IOP.0000000000002029 pmid:34238823

    CrossRefPubMed
34. 34.↵
    1. Steele L,
    2. Zbeidy S,
    3. Thomson J, et al

    . How is the term haemangioma used in the literature? An evaluation against the revised ISSVA classification. Pediatr Dermatol 2019;36:628–33 doi:10.1111/pde.13885 pmid:31318089

    CrossRefPubMed
35. 35.↵
    1. Elbaze S,
    2. Duron L,
    3. Mambour N, et al

    . A signature of structural MRI features at 3 Tesla allows an accurate characterization of orbital cavernous venous malformation. Eur Radiol 2023;33:2149–59 doi:10.1007/s00330-022-09163-x pmid:36264311

    CrossRefPubMed
36. 36.↵
    1. Xian J,
    2. Zhang Z,
    3. Wang Z, et al

    . Value of MR imaging in the differentiation of benign and malignant orbital tumors in adults. Eur Radiol 2010;20:1692–702 doi:10.1007/s00330-009-1711-0 pmid:20131055

    CrossRefPubMed
37. 37.↵
    1. Lecler A,
    2. Duron L,
    3. Balvay D, et al

    . Combining multiple magnetic resonance imaging sequences provides independent reproducible radiomics features. Sci Rep 2019;9:2068 doi:10.1038/s41598-018-37984-8 pmid:30765732

    CrossRefPubMed
38. 38.↵
    1. Lecler A,
    2. Duron L,
    3. Charlson E, et al

    . Comparison between 7 Tesla and 3 Tesla MRI for characterizing orbital lesions. Diagn Interv Imaging 2022;103:433–39 doi:10.1016/j.diii.2022.03.007 pmid:35410799

    CrossRefPubMed
39. 39.↵
    1. Duron L,
    2. Heraud A,
    3. Charbonneau F, et al

    . A magnetic resonance imaging radiomics signature to distinguish benign from malignant orbital lesions. Invest Radiol 2021;56:173–80 doi:10.1097/RLI.0000000000000722 pmid:32932375

    CrossRefPubMed
40. 40.↵
    1. Duron L,
    2. Savatovsky J,
    3. Fournier L, et al

    . Can we use radiomics in ultrasound imaging? Impact of preprocessing on feature repeatability. Diagn Interv Imaging 2021;102:659–67 doi:10.1016/j.diii.2021.10.004 pmid:34690106

    CrossRefPubMed